A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc.
Eli Lilly and Company
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Genzada Pharmaceuticals USA, Inc.
Montefiore Medical Center
Jules Bordet Institute
PharmaMar
National Cancer Institute (NCI)
NYU Langone Health